InflaRx (IFRX) to Release Earnings on Wednesday

InflaRx (NASDAQ:IFRX) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $0.03 million for the quarter.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Stock Performance

NASDAQ IFRX opened at $1.85 on Friday. The stock has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.82. InflaRx has a one year low of $0.82 and a one year high of $2.82. The company has a market capitalization of $124.20 million, a P/E ratio of -1.71 and a beta of 2.21.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st. Cantor Fitzgerald assumed coverage on InflaRx in a research note on Tuesday. They set an “overweight” rating and a $10.00 price objective on the stock. Finally, Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 26th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.